TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1521049
Drug: Cigarette yield,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics
Study: 2146242
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g spectinomycin
Study: 3156805
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ceftriaxone
Study: 30035423
Drug: Speroton complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speroton complex with general therapy
Study: 30035423
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy (Control Group)
Study: 27484782
Drug: LED-RL phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LED-RL phototherapy at doses of 160 J/cm², 320 J/cm², 480 J/cm², and 640 J/cm²
Study: 25236915
Drug: Vilazodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (5 mg) with ketoconazole (200 mg once daily)
Study: 25236915
Drug: Vilazodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (10 mg) with ketoconazole (200 mg once daily)
Study: 25236915
Drug: Vilazodone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (40 mg once daily) with carbamazepine (steady-state)
Study: 15206537
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with bisphosphonates
Study: 9389897
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (Mg(OH)2; 411-548 mg Mg/d)
Study: 8198658
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous loading dose of phenytoin
Study: 8198658
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral phenytoin supplementation
Study: 8198658
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous loading dose of phenytoin (entire group analysis)
Study: 27542303
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg/kg per h, from ICU admission on the day of surgery until 0800 h on postoperative day 1)
Study: 27542303
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg/kg per h)
Study: 18715160
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by standard single dose of PPV23 (unprimed group)
Study: 12679174
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d plant stanol (3.4 g of stanol ester)
Study: 12679174
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d plant stanol (5.1 g of stanol ester)
Study: 11122545
Drug: Early triage
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early triage angiography and subsequent therapies based on the angiogram
Study: 9169300
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 +/- 2.5 mg/day, 10 +/- 2.5 mg/day, 15 +/- 2.5 mg/day)
Study: 1383071
Drug: rIFN-alpha therapy
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha therapy
Study: 29532078
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (TODAY)
Study: 27002003
Drug: Morphine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine Group (10 mg bupivacaine 0.5% and 0.5 mg morphine)
Study: 27002003
Drug: Morphine-Dex Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-Dex Group (10 mg bupivacaine 0.5%, 0.5 mg morphine and 5 µg dexmedetomidine)
Study: 27002003
Drug: Bupivacaine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine Group (10 mg bupivacaine 0.5%)
Study: 25298196
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to group therapy
Study: 25298196
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to individual web-based tobacco treatment
Study: 20357370
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/day for younger girls and 850 mg/day for older girls)
Study: 19338489
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (1 g twice daily) in combination with cyclosporine and steroids (impaired group)
Study: 15793608
Drug: Aggressive LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive LDL-C lowering (high-dose lovastatin therapy)
Study: 15793608
Drug: Moderate LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate LDL-C lowering (low-dose lovastatin therapy)
Study: 10088567
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin at 0.043 U/kg per hour
Study: 10088567
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous insulin administration
Study: 1823632
Drug: Melatonin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin therapy (5 mg/m2/day to 700 mg/m2/day in four divided doses)
Study: 1823632
Drug: Melatonin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin therapy
Study: 6367857
Drug: L-PAM (L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PAM (L-phenylalanine mustard) for 2 years
Study: 27075913
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 600 μg/d
Study: 22591408
Drug: Neurosurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurosurgical treatment for SAH
Study: 20349685
Drug: Sertaconazole nitrate
Normalized name: Sertaconazole Nitrate
DrugBank: Sertaconazole (DB01153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertaconazole nitrate cream 2%
Study: 16452557
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (blood glucose levels normalized to 80 to 110 mg/dL using insulin infusion)
Study: 16452557
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (for patients staying in ICU for three or more days)
Study: 16452557
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (insulin administered when blood glucose exceeded 215 mg/dL)
Study: 11232529
Drug: Capozide-50 (C-50)
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capozide-50 (C-50) + melatonin (3 mg at 10.00 p.m.)
Study: 8737131
Drug: Sparfloxacin 200
Normalized name: sparfloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 200 mg
Study: 18093254
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg kg(‐1) pyrazinamide
Study: 18093254
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg kg(‐1) pyrazinamide
Study: 12589392
Drug: Delta(9)-THC (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta(9)-THC (up to 10 mg)
Study: 8615355
Drug: all-rac-alpha-tocopheryl acetate
Normalized name: all-rac-alpha-tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all-rac-alpha-tocopheryl acetate (400 mg, n = 10)
Study: 8615355
Drug: water-miscible preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: water-miscible preparation (400 mg, n = 9)
Study: 8615355
Drug: All preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All preparations (A, B, C)
Study: 6425911
Drug: Combined thioridazine
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined thioridazine (100 mg THI/day for the first 7 days) and desipramine (200 mg DMI/day for 21 days)
Study: 6425911
Drug: Desipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (200 mg DMI/day for 21 days)
Study: 23978222
Drug: Midodrine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (2.5 to 10 mg three times daily for 2 weeks)
Study: 22325733
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 6000 mg
Study: 19085624
Drug: Single-dose maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose maternal methadone administration
Study: 19085624
Drug: Split-dose maternal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose maternal methadone administration
Study: 17466338
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine (APO) 4 mg
Study: 11291581
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments from the Health Education and Research Trial (HEART) Project
Study: 8390768
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of alpha lipoic acid daily for 3 months
Study: 8390768
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of selenium (sodium selenite) daily for 3 months
Study: 8390768
Drug: 1200 IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 IE of D‐alpha‐tocopherol daily for 3 months
Study: 3105472
Drug: cromoglycate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cromoglycate (20 mg)
Study: 24338893
Drug: Cholesterol-lowering therapy
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapy (Pravastatin)
Study: 22816385
Drug: Okada Purifying
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okada Purifying Therapy (OPT)
Study: 15617591
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living and work status
Study: 12518489
Drug: Oral-B Battery
Normalized name: BATTERY,DISPOSABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Battery
Study: 12518489
Drug: Oral-B 3-D
Normalized name: trans-resveratrol 3-β-D-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 3-D Excel
Study: 10354193
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment by cardiologists and general practitioners
Study: 7853578
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mitomycin C
Study: 7853578
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxorubicin
Study: 7853578
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (no maintenance)
Study: 7853578
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment (either immediate or delayed)
Study: 1960560
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy (RT) to all initially involved nodal sites (total dose of 2,000 cGy, with an optional boost of 1,000 cGy)
Study: 1960560
Drug: Partial or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial or no radiation therapy
Study: 6121683
Drug: Beta-blocker drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker drugs
Study: 6121683
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for mild hypertension
Study: 21479818
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of clear liquids (group A; 92 patients)
Study: 21479818
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL of aqueous sodium phosphate (group B; 89 patients)
Study: 21479818
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of polyethylene glycol electrolyte solution (group C; 92 patients)
Study: 17550132
Drug: 5-FU +
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU + low-dose CDDP (n=75)
Study: 10746493
Drug: Daily regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen: sulfadiazine (1 g twice a day) + 25 mg pyrimethamine + 15 mg folinic acid daily; n = 58
Study: 10746493
Drug: Thrice-weekly regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly regimen: sulfadiazine (1 g thrice a week) + 50 mg pyrimethamine + 15 mg folinic acid thrice a week; n = 66
Study: 10746493
Drug: Not taking
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not taking antiretroviral therapy
Study: 1529149
Drug: Acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 800 mg five times daily for 5 days
Study: 27145828
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal therapy with Er,Cr:YSGG laser application (Group 2)
Study: 27145828
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal therapy (Group 1)
Study: 23821423
Drug: Rehabilitation exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation exercises (60 minutes, twice a week for 12 weeks)
Study: 20498389
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg/d
Study: 20498389
Drug: Citalopram 30
Normalized name: citalopram 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 30 mg/d
Study: 19021006
Drug: 1 gr
Normalized name: Pro-Stat 101 Grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gr i.v. paracetamol infusion 15 minutes before induction (Group I)
Study: 19021006
Drug: i.v. Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Paracetamol infusion started 15 minutes before the end of surgery (Group II)
Study: 17233365
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine administered at 8-hour intervals postoperatively
Study: 3865492
Drug: Cefaclor (Kefolor),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (Kefolor), 20 mg/kg body weight b.i.d. for 10 days
Study: 29108736
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose solution (2 mL of 88% sucrose)
Study: 12401614
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL)
Study: 19040446
Drug: Chinbone augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinbone augmentation with Bio-Gide membrane
Study: 19040446
Drug: Chinbone augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinbone augmentation without Bio-Gide membrane
Study: 19040446
Drug: Bio-Oss augmentation
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Oss augmentation with Bio-Gide membrane
Study: 19040446
Drug: Combined augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined augmentation techniques
Study: 19040446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no augmentation techniques mentioned)
Study: 12811710
Drug: Superactivated charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superactivated charcoal (SAC) 75 g administered orally as a slurry in 8 oz of apple juice 3 hours after acetaminophen ingestion
Study: 12811710
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SAC administered)
Study: 11154093
Drug: Tolcapone (TOL)
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone (TOL) 600 mg
Study: 8957270
Drug: Semilente insulin
Normalized name: INSULIN,SEMILENTE,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semilente insulin
Study: 1530675
Drug: Product 1
Normalized name: calcium polystyrene sulfonate product 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 1 (20 mg nifedipine)
Study: 1530675
Drug: Product 2
Normalized name: Cytra 2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 2 (20 mg nifedipine)
Study: 2862713
Drug: Ceftazidime (151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (151 mg/kg every 8 hours for 12 days)
Study: 2862713
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and Carbenicillin (6.3 mg/kg gentamicin every 8 hours, 450 mg/kg carbenicillin every 6 hours for 10 days)
Study: 31485965
Drug: Medical weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical weight management tools (partial meal replacements, recreation center vouchers, pharmacotherapy, commercial weight loss program vouchers, group behavioral weight loss program) for $5 or $10 monthly.
Study: 31485965
Drug: On-treatment participants
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment participants (those actively using the tools).
Study: 29729171
Drug: Vedolizumab infusions
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab infusions
Study: 27461877
Drug: Inert cream
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert cream applied on the right hand during verbal session
Study: 27461877
Drug: Inert cream
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert cream applied on the right hand during conditioning session
Study: 20026457
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg plus dexamethasone 20 mg
Study: 20026457
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg plus dexamethasone 20 mg
Study: 8551533
Drug: Neuromuscular biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular biofeedback therapy
Study: 8551533
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise programs (post-therapy)
Study: 24750268
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (10000-lux light box, 30 min in the morning, three times a week for 4 weeks)
Study: 24750268
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care without light therapy
Study: 23803704
Drug: BHT‐3021 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT‐3021 (0.3, 1.0, 3.0, and 6.0 mg)
Study: 16730170
Drug: 750-mg levofloxacin
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750-mg levofloxacin for 5 days
Study: 16730170
Drug: 500-mg levofloxacin
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg levofloxacin for 10 days
Study: 11251523
Drug: Desmopressin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (40 microg, nasal spray)
Study: 2801591
Drug: Multivitamin with
Normalized name: multivitamin with iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin with 18 mg Fe
Study: 357128
Drug: Apomorphine-L-dopa-carbidopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine-L-dopa-carbidopa
Study: 31220105
Drug: γ-PGA 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-PGA 1,500 mg for 4 weeks
Study: 25886286
Drug: Multi-component school-based
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component school-based intervention including curriculum component, mandatory daily hand washing before lunch, extra cleaning of school toilets
Study: 9000189
Drug: Nonsteroidal antiandrogens
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiandrogens (NSAAs) plus luteinizing hormone-releasing hormone (LHRH) or orchiectomy
Study: 8229530
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (5 ml/kg) of protein-free synthetic surfactant (Exosurf) for rescue therapy
Study: 8229530
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (5 ml/kg) of protein-free synthetic surfactant (Exosurf) for prophylactic therapy
Study: 8229530
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects for prophylactic therapy
Study: 8229530
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects for rescue therapy
Study: 3743614
Drug: tiapamil 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapamil 300 mg thrice daily
Study: 26521158
Drug: Therapy devices
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy devices with varying stability properties
Study: 22481687
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment plus proton pump inhibitors
Study: 22481687
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors alone
Study: 16132805
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of hormone replacement therapy (HRT)
Study: 16132805
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of hormone replacement therapy (HRT) in women aged 65+